Upjohn's Rogaine Rx-to-OTC switch
This article was originally published in The Rose Sheet
Executive Summary
Will be reviewed by FDA's Nonprescription Drugs Advisory Committee July 27. Upjohn has applied to market Rogaine (minoxidil 2% topical solution) as an over-the-counter drug for use as a hair growth stimulant for men with male pattern baldness. The meeting will begin at 2 p.m. in conference rooms D and E at FDA's Parklawn building